Genetic Testing, Disclosure, and Legal Implications

ABO Compatibility Testing – Related terms #

blood type, immunogenetics. A laboratory analysis that determines the blood group antigens of the intended parents and surrogate to assess risk of allo‑immunization during pregnancy. Example: Matching an O‑negative surrogate with an A‑positive intended mother to prevent hemolytic disease of the newborn. Challenge: Limited predictive value for non‑blood‑related genetic disorders, yet often required by clinics.

Accredited Genetic Laboratory – Related terms #

CLIA, ISO 15189. Facility that meets national quality standards for performing genetic tests, ensuring reliability of results used in surrogacy contracts. Practical application: Courts may require proof that a carrier screening was performed in an accredited lab before accepting a surrogacy agreement. Challenge: Access to accredited labs can be costly for international surrogacy arrangements.

Allele Frequency – Related terms #

population genetics, carrier rate. The proportion of a specific genetic variant within a defined population, used to estimate the likelihood that a surrogate or donor carries a recessive disorder. Example: The cystic fibrosis ΔF508 allele has a frequency of 1 in 25 among Northern Europeans. Challenge: In multi‑ethnic surrogacy cases, determining appropriate reference populations can be complex.

Amniocentesis – Related terms #

prenatal diagnosis, fetal DNA. Invasive procedure performed between 15–20 weeks gestation to retrieve amniotic fluid for genetic testing of the fetus. Practical use: Detecting trisomy 21 or single‑gene disorders when pre‑implantation genetic testing was not performed. Challenge: Small risk of miscarriage may affect the surrogate’s willingness to consent.

American College of Medical Genetics and Genomics (ACMG) Guidelines – Rel… #

Authoritative recommendations for interpretation of genetic test results, including the five‑tier classification system (pathogenic to benign). Example: Using ACMG criteria to decide whether a variant discovered in a surrogate warrants disclosure to intended parents. Challenge: Variability in guideline adoption across jurisdictions can lead to inconsistent legal obligations.

Anonymous Donor Disclosure – Related terms #

identity release, privacy rights. Legal framework governing whether genetic information about an anonymous sperm or egg donor must be shared with the child or surrogate. Practical application: Some jurisdictions require disclosure of carrier status for serious conditions. Challenge: Balancing donor anonymity with the child’s right to health information.

Assisted Reproductive Technology (ART) – Related terms #

IVF, ICSI. Broad term encompassing all medical procedures used to achieve pregnancy, including those that involve genetic testing. Example: Incorporating pre‑implantation genetic testing (PGT) into an IVF cycle for a surrogacy arrangement. Challenge: Different legal definitions of ART across states affect contract enforceability.

Biobanking of Surrogate Samples – Related terms #

DNA repository, consent. The storage of biological specimens (blood, saliva) from surrogates for future genetic testing or research. Practical use: Retaining samples for re‑analysis if new disease‑associated variants are discovered. Challenge: Ensuring informed consent and compliance with data‑protection laws such as GDPR.

Carrier Screening – Related terms #

recessive disorders, pre‑conception testing. Genetic test that identifies whether an individual carries a pathogenic variant for an autosomal recessive condition. Example: Screening surrogate and intended parents for sickle‑cell disease before embryo creation. Challenge: Deciding which panel of conditions is “reasonable” for disclosure in a surrogacy contract.

Case Law on Genetic Disclosure – Related terms #

precedent, duty of care. Judicial decisions that shape the legal duties of parties to disclose genetic information in surrogacy contexts. Example: A court ruling that a surrogate must disclose a previously unknown BRCA1 mutation to the intended mother. Challenge: Rapid evolution of genetics outpaces the development of binding case law, creating uncertainty.

Clinical Utility – Related terms #

actionability, benefit. The extent to which a genetic test result can inform medical management or reproductive decisions. Practical application: Disclosing a pathogenic variant with established preventive measures (e.G., Prophylactic mastectomy for BRCA2). Challenge: Many variants of uncertain significance (VUS) lack clear clinical utility, complicating disclosure obligations.

Confidentiality Clause – Related terms #

contractual provision, privacy. Provision in a surrogacy agreement that obligates parties to keep genetic test results private, except where disclosure is legally required. Example: A clause that limits sharing of the surrogate’s carrier status with third parties. Challenge: Balancing confidentiality with the child’s future right to know medically relevant information.

Consent for Genetic Testing – Related terms #

informed consent, autonomy. Formal agreement by the surrogate (or intended parents) to undergo specific genetic analyses, outlining scope, risks, and data use. Practical use: Obtaining written consent before performing whole‑exome sequencing on the surrogate. Challenge: Ensuring comprehension of complex genetic concepts, especially when language barriers exist.

Contractual Disclosure Obligation – Related terms #

duty to inform, material fact. Legal requirement, often embedded in surrogacy contracts, that parties disclose significant genetic findings that could affect the health of the child or the parties’ decisions. Example: Requiring the surrogate to disclose any newly identified pathogenic variant discovered during pregnancy. Challenge: Defining what constitutes a “material” genetic finding amid evolving scientific knowledge.

Cross‑Border Surrogacy – Related terms #

jurisdictional conflict, extraterritorial enforcement. Arrangement where the surrogate resides in a different country from the intended parents, raising complex issues for genetic testing standards and disclosure. Practical application: Aligning testing protocols with the stricter standards of the intended parents’ home country. Challenge: Reconciling disparate legal regimes on data protection, consent, and child‑birth registration.

DNA Paternity Testing – Related terms #

relationship verification, forensic genetics. Post‑birth analysis to confirm biological relationship between child and intended father, sometimes required when the surrogate’s own DNA is mixed with donor gametes. Example: Using short tandem repeat (STR) profiling to verify the intended father’s contribution. Challenge: Potential emotional distress and legal disputes if results differ from expectations.

DNA Privacy Laws – Related terms #

HIPAA, GDPR. Statutes that regulate the collection, storage, and sharing of genetic information, influencing how surrogacy parties handle test results. Practical use: Implementing encryption and access controls for genetic data in compliance with GDPR’s “right to be forgotten.” Challenge: Differing definitions of “genetic data” across jurisdictions may lead to inadvertent breaches.

Direct‑to‑Consumer (DTC) Genetic Testing – Related terms #

personal genomics, consumer autonomy. Genetic tests sold directly to individuals without a healthcare professional intermediary. Example: A surrogate ordering a DTC carrier test for thalassemia. Challenge: Results may lack clinical validation, raising questions about their admissibility in legal proceedings.

Disability Rights Act (DRA) Implications – Related terms #

non‑discrimination, reasonable accommodation. Legislation that may affect how genetic information is used in surrogacy contracts, prohibiting exclusion of individuals based solely on genetic predispositions. Practical application: Avoiding contract clauses that deny a surrogate’s participation solely because she carries a VUS. Challenge: Interpreting “reasonable accommodation” for prenatal care needs linked to genetic findings.

Doctor‑Patient Confidentiality in Surrogacy – Related terms #

medical privilege, disclosure exception. Legal principle that protects a surrogate’s medical information from disclosure, unless overridden by statutory duties to disclose genetic risks. Example: A fertility specialist may be compelled to share a surrogate’s pathogenic variant with intended parents under a court order. Challenge: Navigating conflicting duties of confidentiality and child welfare.

Duty of Care – Related terms #

negligence, standard of practice. Legal obligation of parties (e.G., Clinicians, agencies) to act with reasonable prudence in providing genetic testing and counseling. Practical use: Ensuring that a surrogate receives counseling about the implications of a discovered BRCA mutation. Challenge: Defining the “reasonable” level of counseling when evidence is still emerging.

Electronic Health Records (EHR) Integration – Related terms #

interoperability, data sharing. Incorporating genetic test results into digital medical files accessible to authorized surrogacy stakeholders. Example: Uploading the surrogate’s carrier screening results to a secure EHR portal shared with the intended parents. Challenge: Maintaining data security while allowing necessary access across international borders.

Embryo Genetic Testing (Pre‑implantation Genetic Testing, PGT) – Related… #

Techniques used to screen embryos for aneuploidy, monogenic disorders, or structural rearrangements before transfer. Practical application: Selecting an embryo free of a known autosomal recessive disease when the surrogate carries a carrier status. Challenge: Legal disputes may arise if a transferred embryo later exhibits a disorder despite negative PGT results.

Ethical Review Board (ERB) Approval – Related terms #

institutional review, research ethics. Formal authorization required for research‑related genetic testing involving surrogates, ensuring protection of participants’ rights. Example: Obtaining ERB clearance before conducting whole‑genome sequencing on surplus embryo tissue. Challenge: Differing ERB standards across countries can delay multinational surrogacy projects.

Expanded Carrier Screening (ECS) – Related terms #

multigene panel, pan‑ethnic testing. Broad testing that assesses carrier status for dozens to hundreds of recessive conditions regardless of ancestry. Practical use: Offering ECS to both surrogate and intended parents to minimize surprise genetic incompatibilities. Challenge: Interpreting incidental findings and deciding which results must be disclosed under contractual obligations.

Family Law Jurisdiction – Related terms #

parental rights, custody. The legal arena that determines who is recognized as the legal parent(s) of a child born via surrogacy, often intersecting with genetic information. Example: A court may rely on genetic testing to affirm the intended mother’s maternity when gestational surrogacy is contested. Challenge: Inconsistent rulings across states create uncertainty for cross‑state surrogacy agreements.

Genetic Counseling – Related terms #

risk communication, psychosocial support. Professional service that interprets genetic test results, explains implications, and assists decision‑making for surrogates and intended parents. Practical application: Counseling a surrogate who learns she carries a pathogenic variant for hypertrophic cardiomyopathy. Challenge: Limited availability of counselors trained specifically in surrogacy contexts.

Genetic Data Ownership – Related terms #

property rights, data stewardship. Conceptual framework defining who holds the legal rights to genetic information produced during surrogacy. Example: A clause stating that the intended parents own the child’s genomic data after birth. Challenge: Conflicts arise when the surrogate wishes to retain control over her own DNA samples.

Genetic Discrimination – Related terms #

employment bias, insurance underwriting. Unfair treatment based on genetic predispositions, potentially influencing surrogacy contracts that attempt to exclude carriers of certain variants. Practical use: Drafting contract language that avoids blanket bans on carriers of non‑actionable variants. Challenge: Ensuring compliance with anti‑discrimination statutes while protecting child health.

Genetic Exceptionalism – Related terms #

privacy paradigm, special protection. The view that genetic information warrants higher privacy safeguards than other medical data. Example: Applying stricter consent procedures for whole‑genome sequencing of a surrogate. Challenge: Critics argue that exceptionalism may hinder beneficial data sharing for child health.

Genetic Information Nondiscrimination Act (GINA) – Related terms #

U.S. Federal law, health insurance. Statute prohibiting health insurers and employers from using genetic information to make coverage or employment decisions. Practical application: Ensuring that a surrogate’s carrier status cannot be used to deny her health insurance. Challenge: GINA does not cover life or disability insurance, leaving gaps in protection.

Genetic Liability Insurance – Related terms #

professional indemnity, malpractice. Insurance policies that protect clinicians and agencies against claims arising from alleged failures in genetic testing or disclosure. Example: A fertility clinic purchasing liability coverage for errors in PGT interpretation. Challenge: Premiums may be high due to the emerging nature of genetic litigation.

Genomic Imprinting – Related terms #

epigenetics, parent‑of‑origin effect. Phenomenon where gene expression depends on whether the allele is inherited from the mother or father, relevant in surrogacy when donor gametes are used. Practical use: Testing for imprinting disorders such as Prader‑Willi syndrome before embryo transfer. Challenge: Imprinting defects may not be detected by standard carrier screens, complicating disclosure.

Genotype‑Phenotype Correlation – Related terms #

penetrance, expressivity. Relationship between a specific genetic variant and the observable traits or disease severity. Example: A surrogate with a pathogenic MYH7 variant may develop cardiomyopathy later, affecting pregnancy monitoring. Challenge: Uncertain correlations can lead to over‑ or under‑disclosure of risk.

International Surrogacy Registry (ISR) – Related terms #

global database, transparency. Centralized platform that records surrogacy agreements, genetic testing outcomes, and disclosure practices across countries. Practical application: Agencies use ISR data to benchmark their genetic counseling protocols. Challenge: Participation is voluntary; data completeness varies widely.

Joint Custody Agreements – Related terms #

co‑parenting, legal parentage. Legal arrangements that define shared parental rights for a child born via surrogacy, often referencing genetic relatedness as a factor. Example: A contract stipulating that the intended mother’s genetic link (through egg donation) grants her primary custody. Challenge: Courts may prioritize gestational connection over genetic link, leading to disputes.

Karyotype Analysis – Related terms #

chromosomal abnormalities, prenatal screening. Laboratory test that visualizes the number and structure of chromosomes in a cell, used to detect aneuploidies in the surrogate’s embryos or fetus. Practical use: Identifying Turner syndrome early in pregnancy. Challenge: Limited resolution may miss sub‑microscopic deletions that could be clinically relevant.

Legal Standard of Proof for Genetic Disclosure – Related terms #

preponderance of evidence, clear and convincing. Burden of proof required to demonstrate that a party failed to disclose material genetic information. Example: A plaintiff must show that the surrogate’s undisclosed pathogenic variant directly caused harm to the child. Challenge: Proving causation when multiple genetic and environmental factors are involved.

Maternal‑Fetal Conflict – Related terms #

ethical dilemma, autonomy. Situation where the surrogate’s health interests diverge from those of the intended child, often arising from genetic risk. Practical application: Deciding whether to continue a pregnancy when the surrogate carries a high‑risk cardiac variant. Challenge: Legal frameworks may prioritize the surrogate’s bodily autonomy over fetal interests.

Medical Necessity Exception – Related terms #

insurance coverage, statutory carve‑out. Provision that allows insurers to cover genetic testing deemed essential for the health of the surrogate or child, even if not otherwise required. Example: Coverage for prenatal whole‑genome sequencing after a VUS is identified. Challenge: Determining “necessity” can be subjective and vary by insurer.

Minority Population Genetic Panels – Related terms #

ethnic‑specific testing, health disparities. Customized carrier screens targeting variants prevalent in specific under‑represented groups. Practical use: Including sickle‑cell disease genes in panels for African‑American surrogates. Challenge: Limited data may lead to false‑negative results, affecting informed consent.

National Surrogacy Act (NSA) – Related terms #

statutory framework, licensing. Hypothetical legislation that standardizes surrogacy practices, including mandatory genetic testing and disclosure protocols. Example: NSA requiring all surrogacy agencies to provide a genetic counseling report before contract signing. Challenge: Enforcement across private and cross‑border arrangements can be uneven.

Non‑Invasive Prenatal Testing (NIPT) – Related terms #

cell‑free DNA, maternal plasma. Screening test that analyzes fetal DNA fragments circulating in the surrogate’s blood to detect common aneuploidies and selected single‑gene disorders. Practical application: Early detection of Down syndrome without amniocentesis. Challenge: Limited ability to detect recessive carrier status, necessitating additional testing.

Obligation to Update Genetic Information – Related terms #

continuous disclosure, dynamic data. Contractual or statutory requirement that parties share new genetic findings that emerge after the initial testing, such as re‑classification of a VUS to pathogenic. Example: A lab re‑classifies a variant in the surrogate’s BRCA2 gene; the updated result must be disclosed within 30 days. Challenge: Tracking and communicating updates across international timelines.

Off‑Label Genetic Test Use – Related terms #

regulatory compliance, experimental application. Applying a genetic test for a purpose not approved by the governing health authority. Practical use: Using a cancer panel to screen a surrogate’s germline DNA for unrelated metabolic disorders. Challenge: Liability may increase if off‑label results are relied upon in legal decisions.

Parental Genetic Responsibility – Related terms #

duty of care, preventive health. Ethical and legal concept that intended parents have an obligation to minimize genetic risk to the child, often by selecting embryos free of known pathogenic variants. Example: Refusing to use an embryo carrying a lethal recessive allele. Challenge: Balancing reproductive autonomy with societal expectations of “genetic perfection.”

Patient‑Generated Health Data (PGHD) – Related terms #

wearables, home testing kits. Health information collected by the surrogate herself (e.G., At‑home genetic test results) and shared with clinicians. Practical application: A surrogate uploads her DTC carrier test PDF to the clinic portal. Challenge: Verifying accuracy and integrating PGHD into formal medical records.

Pre‑Conception Genetic Counseling (PCGC) – Related terms #

risk assessment, reproductive planning. Counseling session offered before IVF or surrogacy to discuss genetic risks, testing options, and reproductive choices. Example: Discussing the implications of a heterozygous CFTR mutation in the intended mother. Challenge: Time constraints and insurance coverage may limit access to PCGC.

Pre‑implantation Genetic Diagnosis (PGD) – Related terms #

embryo biopsy, allele selection. Targeted testing of embryos for a specific known familial mutation, allowing selection of unaffected embryos for transfer. Practical use: Avoiding transmission of Huntington’s disease when the intended father is a known carrier. Challenge: Legal restrictions in some jurisdictions prohibit selection based on non‑medical traits.

Privacy‑by‑Design in Genetic Data Systems – Related terms #

data minimization, security architecture. Engineering approach that embeds privacy protections into the technology used for storing and transmitting genetic results. Example: Using end‑to‑end encryption for surrogate‑parent data exchange platforms. Challenge: Ensuring compliance without compromising usability for clinicians.

Probabilistic Risk Communication – Related terms #

relative risk, absolute risk. Method of conveying genetic risk in terms that reflect uncertainty (e.G., “1 In 200 chance”). Practical application: Explaining to intended parents the residual risk after a negative PGT‑SR result. Challenge: Misinterpretation can lead to unnecessary anxiety or false reassurance.

Qualified Genetic Professional (QGP) – Related terms #

certified genetic counselor, clinical geneticist. Individual authorized by law or professional bodies to interpret genetic test results and provide counseling. Example: A QGP must be present when disclosing a pathogenic variant found in the surrogate’s genome. Challenge: Shortage of QGPs in regions with high surrogacy activity.

Re‑classification of Genetic Variants – Related terms #

VUS upgrade, pathogenic downgrade. Process by which a variant’s clinical significance is updated as new evidence emerges. Practical use: Updating a surrogate’s record when a VUS is later deemed benign, reducing unnecessary disclosure. Challenge: Maintaining a systematic notification system across borders.

Regulatory Harmonization Initiative (RHI) – Related terms #

international standards, mutual recognition. Collaborative effort among national health authorities to align genetic testing requirements for surrogacy. Example: RHI establishing a common panel of mandatory carrier tests for all signatory countries. Challenge: Reconciling differing ethical stances on embryo selection.

Reproductive Rights Framework – Related terms #

bodily autonomy, family planning. Legal and ethical structure that protects individuals’ decisions regarding reproduction, including the right to access or refuse genetic testing. Practical application: A surrogate exercising her right to decline invasive prenatal testing. Challenge: Conflicts arise when intended parents claim a right to know all genetic information affecting the child.

Risk‑Benefit Analysis in Genetic Testing – Related terms #

clinical decision‑making, ethical appraisal. Systematic evaluation of the potential health advantages of a test against possible harms such as anxiety, discrimination, or procedural risk. Example: Weighing the benefit of early detection of a treatable metabolic disorder versus the risk of false‑positive results. Challenge: Subjectivity in assigning weight to psychosocial outcomes.

Sample Chain‑of‑Custody Documentation – Related terms #

audit trail, forensic integrity. Records that track the handling of biological specimens from collection through analysis, essential for legal admissibility. Practical use: Providing a chain‑of‑custody log when a surrogate’s genetic test result is contested in court. Challenge: Maintaining rigorous documentation across multiple labs and jurisdictions.

Secondary Findings Policy – Related terms #

incidental results, ACMG recommendations. Guidelines that dictate whether and how unexpected clinically relevant variants discovered during broad testing (e.G., Whole‑exome) are disclosed. Example: Disclosing a pathogenic LDLR mutation found incidentally, as it is medically actionable. Challenge: Surrogates may object to learning unrelated health risks, creating consent dilemmas.

Self‑Determination Theory in Surrogacy – Related terms #

motivation, autonomy support. Psychological framework emphasizing individuals’ need for autonomy, competence, and relatedness, relevant to surrogate decision‑making about genetic testing. Practical application: Designing counseling sessions that empower the surrogate to make informed choices. Challenge: Balancing empowerment with contractual obligations to disclose.

Sibling Comparison Studies – Related terms #

genetic epidemiology, penetrance estimation. Research method that compares outcomes among siblings with differing genetic variants, used to refine risk estimates for surrogacy counseling. Example: Analyzing health outcomes of children born from the same surrogate but different embryos. Challenge: Ethical concerns about using surrogate‑derived data without explicit consent.

State‑Level Surrogacy Registries – Related terms #

public database, oversight. Government‑maintained records of surrogacy agreements, births, and associated genetic testing outcomes within a particular jurisdiction. Practical use: Auditing compliance with mandatory carrier screening statutes. Challenge: Data privacy laws may restrict public access to individual genetic information.

Statutory Duty to Disclose Genetic Risks – Related terms #

legislative mandate, material risk. Law that obligates parties to reveal any known genetic condition that could materially affect the child’s health. Example: A statute requiring the surrogate to disclose a confirmed pathogenic mutation for spinal muscular atrophy. Challenge: Defining “material” in the context of low‑penetrance variants.

Surrogate Consent Form for Genetic Testing – Related terms #

informed assent, legal document. Standardized written agreement outlining the scope of genetic analyses, data use, and disclosure expectations. Practical application: Including a clause that the surrogate may withdraw consent for future re‑analysis of stored samples. Challenge: Ensuring the form is understandable across literacy levels and languages.

Surrogacy Agency Liability for Genetic Mis‑Disclosure – Related terms #

negligence, professional responsibility. Potential legal exposure when an agency fails to ensure accurate genetic information is communicated to intended parents. Example: An agency that omits a surrogate’s carrier status for Tay‑Sachs disease. Challenge: Determining the extent of the agency’s duty versus the medical provider’s duty.

Surrogacy Ethics Committee (SEC) – Related terms #

institutional oversight, multidisciplinary review. Body that reviews complex cases involving genetic testing, consent, and disclosure to uphold ethical standards. Practical use: SEC evaluating whether to permit embryo selection based on a non‑medical trait. Challenge: Achieving consensus among members with diverse cultural and religious perspectives.

Therapeutic Misconception in Genetic Counseling – Related terms #

patient expectations, research vs. Care. Situation where a surrogate believes that genetic testing is guaranteed to improve health outcomes, rather than provide risk information. Example: A surrogate expects that a VUS result will be “fixed” by the clinic. Challenge: Counselors must correct misconceptions without undermining trust.

Third‑Party Genetic Data Access – Related terms #

research consortium, data sharing agreements. Permission granted to external entities (e.G., Academic researchers) to use genetic data generated in surrogacy cases. Practical application: Contributing anonymized surrogate‑child genotype data to a rare‑disease registry. Challenge: Obtaining consent that satisfies both privacy laws and research ethics.

Transferable Genetic Findings – Related terms #

familial risk, cascade testing. Genetic results that have implications for biological relatives beyond the surrogate and intended parents. Example: Identifying a pathogenic BRCA1 variant in the surrogate that warrants testing of her siblings. Challenge: Determining who holds the right to disclose such findings under confidentiality clauses.

U.S. Federal vs. State Regulation of Genetic Testing – Related terms #

FDA oversight, state licensing. Dual system where the FDA regulates test devices while individual states may impose additional requirements for clinical use. Practical use: A clinic must comply with both FDA clearance for a PGT assay and a state law mandating carrier screening. Challenge: Navigating conflicting or redundant regulations.

Unintended Genetic Consequences of CRISPR Editing – Related terms #

off‑target effects, germline modification. Potential risks when genome editing technologies are applied to embryos in surrogacy to correct a disease‑causing mutation. Example: Off‑target mutation leading to a novel disorder. Challenge: Legal prohibitions on germline editing in most jurisdictions preclude this practice.

Vaccine‑Related Genetic Testing – Related terms #

pharmacogenomics, immunogenetics. Testing to predict adverse reactions to vaccines administered during pregnancy, increasingly relevant for surrogates. Practical application: Screening for HLA‑B*57:01 Before administering a live‑attenuated vaccine. Challenge: Limited evidence base makes it difficult to justify routine testing.

Variant of Uncertain Significance (VUS) – Related terms #

interpretation uncertainty, re‑evaluation. Genetic alteration whose impact on health is not yet established. Example: A surrogate’s exome reveals a VUS in the COL3A1 gene. Challenge: Deciding whether to disclose a VUS, especially when contractual obligations focus on pathogenic findings only.

Whole‑Genome Sequencing (WGS) in Surrogacy – Related terms #

comprehensive analysis, data volume. Technique that reads nearly all DNA bases, providing exhaustive genetic information for the surrogate, embryo, or fetus. Practical use: Detecting rare structural variants missed by targeted panels. Challenge: Managing the massive amount of data, incidental findings, and high cost.

Yield of Genetic Testing in Surrogacy Cohorts – Related terms #

diagnostic rate, detection efficiency. Statistic measuring the proportion of tests that identify a clinically relevant variant within a specific population. Example: A study reporting a 12% carrier detection rate among 500 surrogates screened for hemoglobinopathies. Challenge: Interpreting yield in the context of test selection and population diversity.

Zero‑Tolerance Policy for Undisclosed Pathogenic Variants – Related terms #

contractual penalty, compliance enforcement. Clause stating that failure to disclose any known pathogenic variant results in contract termination and possible legal action. Practical application: Agencies adopting this policy to ensure full transparency. Challenge: May discourage surrogates from participating if they fear punitive consequences for unknown conditions.